| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
|
J Clin Oncol
|
2009
|
5.11
|
|
2
|
Update on the medical treatment of metastatic renal cell carcinoma.
|
Eur Urol
|
2008
|
2.80
|
|
3
|
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.
|
Eur Urol
|
2007
|
2.21
|
|
4
|
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
|
J Clin Oncol
|
2010
|
2.18
|
|
5
|
Radiation recall: a well recognized but neglected phenomenon.
|
Cancer Treat Rev
|
2005
|
1.85
|
|
6
|
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.
|
PLoS One
|
2009
|
1.84
|
|
7
|
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
|
Eur Urol
|
2007
|
1.70
|
|
8
|
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
|
J Urol
|
2007
|
1.68
|
|
9
|
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
|
J Clin Oncol
|
2004
|
1.67
|
|
10
|
Targeted therapy in renal cell carcinoma.
|
World J Urol
|
2008
|
1.56
|
|
11
|
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
|
Cancer
|
2004
|
1.54
|
|
12
|
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
|
Anticancer Drugs
|
2012
|
1.45
|
|
13
|
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.
|
Mol Cancer Ther
|
2010
|
1.42
|
|
14
|
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
|
Mol Cell Biol
|
2006
|
1.37
|
|
15
|
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
|
Eur Urol
|
2007
|
1.37
|
|
16
|
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site].
|
Bull Cancer
|
2002
|
1.24
|
|
17
|
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
|
Cancer Res
|
2010
|
1.18
|
|
18
|
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
|
Oncology
|
2011
|
1.16
|
|
19
|
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.
|
Clin Genitourin Cancer
|
2009
|
0.97
|
|
20
|
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
|
Ther Drug Monit
|
2005
|
0.96
|
|
21
|
Liver metastases in prostate carcinoma: clinical characteristics and outcome.
|
BJU Int
|
2006
|
0.96
|
|
22
|
Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases.
|
Eur J Cancer
|
2010
|
0.90
|
|
23
|
Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.
|
Eur Urol
|
2006
|
0.89
|
|
24
|
[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
|
Bull Cancer
|
2012
|
0.87
|
|
25
|
Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
|
Cancer Chemother Pharmacol
|
2004
|
0.86
|
|
26
|
Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.
|
Eur Urol
|
2008
|
0.84
|
|
27
|
A mucoepidermoid carcinoma in a young man with intellectual disability: review of oral cancer in people with intellectual disability.
|
Oral Surg Oral Med Oral Pathol Oral Radiol
|
2013
|
0.84
|
|
28
|
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
|
J Thorac Cardiovasc Surg
|
2009
|
0.84
|
|
29
|
Cetuximab in advanced bladder cancer.
|
J Clin Oncol
|
2013
|
0.83
|
|
30
|
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.
|
Clin Chem
|
2003
|
0.83
|
|
31
|
Individual adaptive dosing of topotecan in ovarian cancer.
|
Clin Cancer Res
|
2002
|
0.83
|
|
32
|
Hepatic metastases from carcinomas of unknown primary site.
|
Gastroenterol Clin Biol
|
2005
|
0.82
|
|
33
|
A phase II study of irinotecan in patients with advanced renal cell carcinoma.
|
Cancer
|
2003
|
0.82
|
|
34
|
Targeted therapies in metastatic renal cancer in 2009.
|
BJU Int
|
2009
|
0.82
|
|
35
|
Kidney cancer pathology in the new context of targeted therapy.
|
Pathobiology
|
2011
|
0.81
|
|
36
|
Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
|
Cancer Chemother Pharmacol
|
2002
|
0.80
|
|
37
|
Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways.
|
Urol Oncol
|
2009
|
0.80
|
|
38
|
Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.
|
J Thorac Oncol
|
2014
|
0.80
|
|
39
|
[What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
|
Prog Urol
|
2006
|
0.79
|
|
40
|
Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.
|
Oncologist
|
2014
|
0.79
|
|
41
|
A lower risk of dying from urological cancer in Down syndrome: clue for cancer protecting genes on chromosome 21.
|
Urol Int
|
2009
|
0.79
|
|
42
|
Prognostic factors for first recurrence in patients with retroperitoneal sarcoma.
|
Urol Oncol
|
2006
|
0.79
|
|
43
|
Awareness on oral cancer in people with intellectual disability.
|
Oral Oncol
|
2012
|
0.79
|
|
44
|
[Penile tumors].
|
Prog Urol
|
2007
|
0.79
|
|
45
|
Abiraterone acetate withdrawal syndrome: does it exist?
|
Case Rep Oncol
|
2012
|
0.78
|
|
46
|
A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer.
|
Anticancer Drugs
|
2002
|
0.78
|
|
47
|
[Renal cell carcinoma and antiangiogenic therapies].
|
Presse Med
|
2007
|
0.77
|
|
48
|
Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.
|
Int J Urol
|
2009
|
0.77
|
|
49
|
Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
|
Eur Urol
|
2007
|
0.77
|
|
50
|
Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study.
|
Aging Male
|
2014
|
0.77
|
|
51
|
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.
|
Oncol Rep
|
2005
|
0.76
|
|
52
|
[Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination].
|
Bull Cancer
|
2002
|
0.76
|
|
53
|
[Role of PPARgamma in the control of prostate cancer growth: a new approach for therapy].
|
Bull Cancer
|
2007
|
0.76
|
|
54
|
[Chemotherapy in castrate-resistant metastatic prostate cancer].
|
Rev Prat
|
2013
|
0.76
|
|
55
|
[Testicular tumors].
|
Prog Urol
|
2007
|
0.76
|
|
56
|
New therapies in renal cell carcinoma.
|
Curr Opin Support Palliat Care
|
2007
|
0.75
|
|
57
|
Editorial Comment to Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.
|
Int J Urol
|
2015
|
0.75
|
|
58
|
Androgen deprivation therapy for node-positive prostate cancer: adjuvant does not mean salvage.
|
J Clin Oncol
|
2009
|
0.75
|
|
59
|
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
|
Bull Cancer
|
2003
|
0.75
|
|
60
|
Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer tumors of the testis.
|
Eur Urol
|
2007
|
0.75
|
|
61
|
Editorial comment.
|
Eur Urol
|
2006
|
0.75
|
|
62
|
Familial primary mediastinal nonseminomatous germ-cell tumors.
|
Urol Oncol
|
2004
|
0.75
|
|
63
|
Words of wisdom. Re: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
|
Eur Urol
|
2011
|
0.75
|
|
64
|
A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
|
Anticancer Res
|
2010
|
0.75
|
|
65
|
[Towards the individualisation of prescriptions in oncology: urogenital cancers].
|
Bull Cancer
|
2008
|
0.75
|
|
66
|
[Prostatic cancer and pelvic node involvement: a unambiguous disease?].
|
Prog Urol
|
2006
|
0.75
|
|
67
|
[Neoadjuvant chemotherapy for urothelial tumors].
|
Rev Prat
|
2014
|
0.75
|
|
68
|
Neoadjuvant chemotherapy in muscle-invasive bladder cancer: ready for prime time?
|
Crit Rev Oncol Hematol
|
2012
|
0.75
|
|
69
|
[Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
|
Prog Urol
|
2002
|
0.75
|
|
70
|
[Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
|
Orv Hetil
|
2012
|
0.75
|
|
71
|
Modeling plasma and saliva topotecan concentration time course using a population approach.
|
Oncol Res
|
2003
|
0.75
|
|
72
|
[Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy].
|
Bull Cancer
|
2008
|
0.75
|
|
73
|
[Testicular tumors].
|
Rev Prat
|
2014
|
0.75
|
|
74
|
[Management of metastatic bladder cancer].
|
Rev Prat
|
2014
|
0.75
|
|
75
|
[Prognostic factors in localized and in metastatic renal cell carcinomas].
|
Prog Urol
|
2007
|
0.75
|
|
76
|
[Treatment of anaemia in medical oncology].
|
Orv Hetil
|
2012
|
0.75
|
|
77
|
[Prostate cancer and acute disseminated intravascular coagulation. Therapeutic management based on three cases].
|
Prog Urol
|
2003
|
0.75
|
|
78
|
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.
|
Anticancer Drugs
|
2006
|
0.75
|
|
79
|
[Bladder cancer and urothelial tumors. New therapeutic strategies].
|
Rev Prat
|
2014
|
0.75
|
|
80
|
In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer.
|
Anticancer Res
|
2006
|
0.75
|
|
81
|
[Urachal cancers].
|
Bull Cancer
|
2013
|
0.75
|
|
82
|
[Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site].
|
Bull Cancer
|
2003
|
0.75
|
|
83
|
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
|
Expert Rev Anticancer Ther
|
2006
|
0.75
|
|
84
|
Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse.
|
Eur J Dermatol
|
2013
|
0.75
|
|
85
|
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
|
Anticancer Drugs
|
2012
|
0.75
|
|
86
|
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
|
Bull Cancer
|
2002
|
0.75
|